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Summary The hormonal mechanisms involved in the development of gynaecomastia accompanying the
treatment of multiple myeloma in adult men have been investigated by studying levels of circulating
testosterone (T), oestrone (El), oestradiol (E2), sex-hormone binding globulin (SHBG), prolactin (PRL) and
the gonadotrophins LH and FSH, before, during and after development of gynaecomastia in 4 men. These
have been compared with 5 closely matched men who did not develop gynaecomastia during similar treatment
for myeloma. Levels ofcirculating T fell, and levels of E1 and E2 rose during treatment periods in all subjects,
and the changes were statistically significant in subjects developing gynaecomastia, which resolved as levels of
sex steriod returned towards normal following cessation of treatment. We conclude that treatment of adult
men for myeloma results in testicular dysfunction with a reduction in circulating T and a rise in circulating
oestrogens. These changes are most marked in subjects developing gynaecomastia in whom the normal breast
tissue is stimulated by a subtle, transient oestrogen:androgen imbalance in favour of oestrogens.
Gynaecomastia may complicate the treatment of
malignant disease by cytotoxic drugs. Combination
chemotherapy with mustine, vinblastine,
procarbazine and prednisolone (MVPP) (see Shalet,
1980, for review), and a number of drugs used
individually, have induced this complication in
adults (Galton et al., 1958; Smith & Barrett, 1967;
Schorer et al., 1978). The breast development in
such patients is thought to be related to
chemotherapy-induced testicular damage, although
the mechanism is unclear. In this study we have
measured levels of the major circulating androgen,
testosterone (T) and the oestrogens, oestrone (El)
and oestradiol (E2), sex-hormone-binding globulin
(SHBG), prolactin (PRL), and the gonadotrophins,
luteinizing hormone (LH) and follicle stimulating
hormone (FSH), before, during, and after the
development of gynaecomastia in men undergoing
treatment ofmultiple myeloma.
Patients
The 9 subjects studied were adult males with
multiple myeloma attending the University of
Manchester Department of Medical Oncology
between 1975-79. During this period 135 patients
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with myeloma presented, of whom 70 were males.
Individual subjects were studied for between 10 and
44 months after diagnosis. Four subjects developed
gynaecomastia during chemotherapy. Five patients
who did not develop gynaecomastia were used as
controls. Subjects and controls were matched for
age, clinical stage of disease, immunologlobulin
class, renal function, type of chemotherapy and
response to chemotherapy, details of which are
given in Table I. None of the subjects recalled
having had gynaecomastia or any testicular disease
previously. All patients received radiotherapy at
some stage during treatment. The estimated scatter
to the testes is shown in Table I. All patients
received 4-6 weekly courses of chemotherapy with
cyclophosphamide (500mgM-2 i.V. on Day 1),
melphalan (6mgM-2 p.o. on Days 1-4) and
prednisolone (60mgM-2 p.o. on Days 1-4).
Supplementary chemotherapy was given to certain
patients, cytosine arabinoside (subjects 1, 2, 3, 4
and 6), adriamycin and CCNU (subject 6) and
vincristine (subject 8). Single blood samples were
also taken from 60 normal men aged 20-76 years
and analysed for T, E1 and E2.
Methods
Blood samples taken in the morning were either
centrifuged immediately or kept at 4°C and
centrifuged within 2-3 hours. Serum was stored at
-20°C until the time of assay.70 D.M. LARGE et al.
Table I Clinical details of subjects
Radiation
Age at scatter to Gynaecomastia
start of No. of testes (cGy) Months after
Controls treatment Myeloma Clinical courses of single Developed Duration starting
Symbol (years) type stage chemotherapy fraction (side) (months) chemotherapy
1. O 48 IgG(K)BJ+ Ila 12 20
2. * 57 *Non-SBJ- hIa 21 0
3. rI 58 IgA(K)BJ+ Illa 9 0
4. * 64 IgA(K)BJ+ Ila 10 120
5. A 73 IgG(K)BJ+ IlIb 19 0
Gynaecomastia
6. * 55 *Non-S-+IgG(A)BJ- hIa 18 10 L 6 13
7. V 56 IgA(K)BJ- Illa 7 10 L 2 6
8. V 64 IgA(K)BJ+ Ila 13 0 L+R 2 11
9. A 73 IgG(K)BJ+ IlIb 6 10 L 3 4
*Non-secretory
Assays
Steroid hormones T, E1 and E2 were measured on
each sample using a multiple steroid fractionation
and radioimmunoassay procedure as previously
described (Large & Anderson, 1979). Specificity was
confirmed for each assay by the method of
Anderson et al. (1976a).
Sex-hormone-binding globulin (SHBG) was
measured by the method of Rosner (1972),
modified by Anderson et al. (1976b) using 3Haot-
dihydrotestosterone as ligand.
Gonadotrophins LH and FSH were measured by
double antibody radioimmunoassay and expressed
as iu-1 of NIBSC standards 68/40 and 78/549
respectively.
Prolactin was measured by a double antibody
radioimmunoassay and expressed as mul- of
NIBSC 75/504.
All assays were subject to quality control on the
Supra-Regional Assay Service Quality Control
Scheme.
Statistical methods
For subjects with gynaecomastia, the change in
loge E2/T (pmolnmol-1) was calculated between
the time just before gynaecomastia developed and
the time immediately preceding this. For control
patients, the time point in the course of treatment
was located which corresponded most closely to
that at which the gynaecomastia subjects developed
the condition. This was done without knowledge of
the E2/T ratios, and the change in loge E2/T
between this and the preceding sample time was
calculated (Table III). Differences in the changes in
the two groups of subjects were compared using a
one-tailed randomisation test, since it was predicted
that the group developing gynaecomastia would
tend to show an increase in the circulating E2/T
ratio before the condition developed.
Results
Normal men
Levels of circulating T fell with advancing age (r=
-0.68; P<0.0001), whereas there was a progressive
increase in levels of E, with age (r=0.56;
P<0.0001). Levels of E2 also rose with age, but
were less well correlated (r=0.28; P=0.03). For the
normal men aged 50-80 years, the mean sex steriod
levels and ranges were as follows:
Testosterone (T):
mean = 14.8nmol1- 1 (2.2-41.0nmolI l) (n=22)
Oestrone (El):
mean =219pmol 1 (95-417pmolI') (n=25)
Oestradiol (E2):
mean = 182pmol 1 (65-388pmo1 1) (n =26)
Degree and duration ofgynaecomastia
Patients developed a mild degree of gynaecomastia
lasting from 2-6 months with minimal local
symptoms. In 3 cases it was unilateral (L side) and
in one case bilateral. It was noticed by the subject
in each case, between 4 and 13 months after
beginning chemotherapy.GYNAECOMASTIA COMPLICATING MYELOMA THERAPY 71
There was no obvious correlation between the
degree and duration of the gynaecomastia and the
magnitude of the preceding or associated hormone
changes except in subject 6 whose gynaecomastia
lasted for 6 months and in whom the greatest rises
in E2 were dected beforehand (Figure 1 h and j *).
This suggests that direct stimulation of breast tissue
by circulating E2 might have occurred. However, no
hormone measurement emerged which could be
used to predict subjects in whom gynaecomastia
might develop during chemotherapy.
Controls and subjects developing gynaecomastia
Profiles of individual hormone levels, before, during
and after chemotherapy are shown in Figure 1 for
controls (a-e) and subjects who developed
gynaecomastia (f-j). The maximum change in mean
circulating sex steroid levels during chemotherapy,
expressed as a percentage of basal levels, for
controls and subjects developing gynaecomastia is
shown in Table II.
Table II Maximum changes in mean
circulating sex steroid level during
chemotherapy, as a percentage of basal levels,
for controls and subjects developing
gynaecomastia.
T El E2
Controls -45% +38% +49%
Gynaecomastia -51% +49% +70%
Basal levels of testosterone in each subject were
within the normal range for adult men. During
chemotherapy T levels fell in every subject
irrespective of whether gynaecomastia subsequently
developed or not. In some subjects there was a fall
to 50% or less of basal values (Figure la 0, 0 and
A). In subjects receiving chemotherapy
continuously for < 12 months, T levels fell
progressively whilst chemotherapy was being given
and rose rapidly after it was withdrawn to levels
very close to basal (Figure la 0 and *).
In subjects developing gynaecomastia, as a group,
T levels fell further than in control subjects. This
was particularly marked in two patients (Figure If
V and V). T levels rose rapidly after withdrawal of
chemotherapy to a level exceeding basal in one
subject (Figure If 7), and during chemotherapy in
one other subject (Figure If V). This did not occur
in any other subject or control. Two subjects
developed gynaecomastia during periods when
circulating T levels were very low. In both subjects
B.J.C.-D
Table III LogeE2/T ratios for gynaecomastia
Time
Subjects points loge (oestradiol/testosterone)
Control t3 t4 t3 t4 Diference
1. 0 2 6 1.812 2.255 0.443
2. * 1 5 2.154 2.281 0.127
3. O 1 7 2.520 2.452 -0.068
4. * 1 3 1.794 1.619 -0.175
5. A 4 12 1.639 1.605 -0.034
Gynae-
comastia tl t2 tl t2
6. * 2 9 2.261 3.160 0.899
7. V 3 4 1.880 3.786 1.906
8. V 9 13 2.268 2.934 0.666
9. A 6 7 1.949 2.078 0.129
Shows the time (in months) after the start of treatment
at which the gynaecomastia developed and the
difference in the loge (oestradiol/testosterone) ratio.
t2=time point immediately before gynaecomastia
developed; tl =time point previous to t2; t4=time
point corresponding to t2 for control patients and t3
=time point previous to t4.
Differences between the change in the ratio logeE2/T
just before gynaecomastia developed, compared to a
corresponding change in control patients were
statistically significant (P=0.016).
this resolved as T levels rose rapidly following
withdrawl ofchemotherapy (Figure lf V and V).
Basal levels of E1 were similar in the two groups
ofmen. There was no significant correlation between
changes in El levels and the development of
gynaecomastia.
Basal levels of E2 were similar in the two groups
and within the normal range for adult men. Levels
in controls rose during chemotherapy, but more
gradually than was the case for El. In contrast,
subjects who developed gynaecomastia showed
greater increases in E2 during chemotherapy.
Gynaecomastia developed in one subject during
such an increase in E2 (Figure 1 h V), and just
afterwards in two others (Figure lh * and A).
Statistically significant differences were found
between the change in logeE2/T just before the
development of gynaecomastia, compared to
corresponding times after the start of treatment in
control subjects (P=0.016).
Basal levels of LH and FSH were similar in the
two groups of men. The administration of
chemotherapy was associated with a rise of FSH
levels in every subject irrespective of age, which fell
again after chemotherapy was stopped.Periods of chemotherapy
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Figure 1 Hormone profiles for controls (a-e) and subjects developing gynaecomastia (f-j). Presence of
gynaecomastia and its duration is indicated by symbols appropriate to individual subjects. (See also Table 1).
72
30
20
10
E
C
0
600 b
200i
0
600 C
400
200
0GYNAECOMASTIA COMPLICATING MYELOMA THERAPY 73
Levels of LH did not change significantly in
control subjects following chemotherapy except in
one man (Figure li *), where LH rose during two
courses of chemotherapy and fell following its
withdrawal. In contrast, LH levels rose rapidly in
most subjects who developed gynaecomastia and
fell to basal values after withdrawal of
chemotherapy (Figure li).
Levels of prolactin did not change significantly in
any control subject during the period of the study.
SHBG levels were within the normal range and
did not change significantly during or after
chemotherapy in any control or subject.
Subjects developed gynaecomastia irrespective of
their age at presentation with myeloma or their age
at onset of chemotherapy, and older men did not
develop the condition more readily than younger.
Discussion
This is the first prospective study in males who
developed gynaecomastia during treatment for
cancer. The aim of this investigation was to
advance our understanding of why gynaecomastia
develops in some but not all men treated for
multiple myeloma. The fall in T and the rise in E1
and E2 with age in normal men and the basal levels
of the sex steroids for the nine subjects are in
agreement with published data (Rubens et al., 1974;
Burger et al., 1974). Basal levels of LH, FSH, and
SHBG are also similar to published data for older
men (Schalch et al., 1968; Rubens et al., 1974;
Anderson, 1974).
We have confirmed the biochemical changes of
compensated Leydig cell dysfunction induced by
chemotherapy (Whitehead et al., 1982). Levels of
circulating T fell and E1, and E2, FSH and LH rose
in all cases, but changes were most marked in men
developing gynaecomastia, suggesting that the
stimulus to breast growth was related to the
severity of testicular damage. Furthermore, a
significant difference between changing E2/T ratios
was identified between subjects with gynaecomastia
and controls, which has not been shown in drug-
induced gynaecomastia in previous studies.
Gynaecomastia resolved when these levels returned
towards normal following withdrawal of
chemotherapy. It is possible, therefore, that the
stimulus to breast growth is related either to an
increased exposure to oestrogen, or a release from
the action of T, which probably normally
suppresses breast growth in men.
The origin of the increased oestrogens in our
subjects remains unclear. It is known, however, that
the human testis secretes E2 and a small amount of
E1 (Baird et al., 1973; Doerr & Pirke, 1974;
Martikainen et al., 1980). Sertoli cells also actively
aromatize androgen to oestrogens following
stimulation by FSH (Dorrington & Armstrong,
1975; Dorrington et al., 1978; Payne et al. 1976).
Whether this is released into the systemic
circulation or is involved in intra-testicular control
mechanisms is unclear.
In view of the present findings, it is possible that
the initial Leydig cell damage and tubular
dysfunction with consequent fall in T and rise in
LH/FSH, resulted in an increase in testicular
oestrogen secretion from surviving Leydig or
Sertoli cells, or both. Furthermore, E2 may itself
regulate inhibitory enzymes on the testicular
androgen biosynthetic pathway, suppressing T
production still further (Saez et al., 1978; Hsueh et
al., 1978; Huhtaniemi et al., 1980). This would
produce an even greater imbalance in the
circulating oestrogen: androgen ratio.
Approximately 50% of the blood production rate of
E2 arises from peripheral conversion of T
(Longcope et al., 1969). Whether chemotherapy
affects this or the rate of excretion of androgens or
oestrogens is unknown, but the possibility cannot
be excluded.
Levels of SHBG did not change significantly in
any subject. This was despite the considerable
reduction in circulating T and the increase in E1
and E2 seen in some subjects who developed
gynaecomastia. Clearly the magnitude and duration
of these changes were insufficient to increase hepatic
SHBG synthesis which might have been expected.
Consequently it is unlikely that the development of
gynaecomastia was related to any change in the
ratio of bound:free T or oestrogens.
Both cyclophosphamide and melphalan are
alkylating agents and this group of cytotoxic drugs
is the most frequently recognised cause of cytotoxic-
induced testicular damage (reviewed by Shalet,
1980). Our patients received both these drugs plus a
certain amount of scatter irradiation to the testes,
which may well have contributed to the subsequent
testicular damage (Rowley et al., 1974). Our study
shows that following such treatment, gynaecomastia
may be associated with resulting testicular damage.
This further illustrates the sensitivity of male breast
tissue to changes in circulating concentrations of
oestrogens and testosterone.
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